Check-Cap (STU:7CC) ROCE %: 311.00% (As of Dec. 2025)


STU:7CC Check-Cap Ltd STU:7CC
25 GF Score
Price €1.15
! 2 Warning Signs
View Full Analysis

What is Check-Cap ROCE %?

Check-Cap STU:7CC +0.88% 25 ROCE % is 311.00% as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Check-Cap's annualized ROCE % for the quarter that ended in Dec. 2025 was 311.00%.

Check-Cap  (STU:7CC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Check-Cap ROCE % Related Terms

Check-Cap ROCE % Historical Data

* Premium members only.

The historical data trend for Check-Cap's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Check-Cap ROCE % Chart

Check-Cap Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.24 -42.24 -52.44 -235.95 472.08

Check-Cap Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.13 -67.25 -479.76 -241.97 311.00
STU:7CC
25GF Score
Check-Cap Ltd STU:7CC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Check-Cap ROCE % Calculation

Check-Cap's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3.694/( ( (0.36 - 1.73) + (6.393 - 3.458) )/ 2 )
=3.694/( (-1.37+2.935)/ 2 )
=3.694/0.7825
=472.08 %

Check-Cap's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=9.658/( ( (4.997 - 1.721) + (6.393 - 3.458) )/ 2 )
=9.658/( ( 3.276 + 2.935 )/ 2 )
=9.658/3.1055
=311.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 311.00% mean?
Check-Cap (STU:7CC) has a ROCE % of 311.00% as of Dec. 2025.
Is Check-Cap's ROCE % too high?
Check-Cap's current ROCE % is 311.00%. Overall, Check-Cap has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's ROCE % compare to XWEL and NDRA?
Check-Cap's ROCE % of 311.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Check-Cap's current ROCE % is 311.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current ROCE % of 311.00%. The current ROCE % is 311.00%. Check-Cap's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current ROCE % is 311.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Check-Cap Business Description

Other Exchanges MBAI:USA
Address 29 Abba Hushi Avenue, P.O. Box 1271, Mount Carmel, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
25GF Score

Get the complete analysis for STU:7CC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.15
Price